Media - Comunicati Stampa

Per le attività relative a Press & Communication prego contattare:
CITYnet communication
Rome, ITALY
press@sifigroup.com

Visita i nostri social channel!

Comunicati Stampa

Per le attività relative a Press & Communication prego contattare: CITYnet communication Rome, ITALY press@sifigroup.com Visita i nostri social channel!

Comunicati Stampa

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM07 Giugno 2022

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS16 Maggio 2022

SIFI and RADICEPURA announce the closure of the International Call For Ideas to design a Green Area and an Educational Park22 Marzo 2022

SIFI Announces the Grant of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis 14 Marzo 2022

SIFI PROVIDES REGULATORY UPDATES FOR AKANTIOR® (POLIHEXANIDE 0.8 MG/ML) IN EUROPE AND THE UNITED STATES15 Febbraio 2022

Comunicati Stampa

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM
07 Giugno 2022

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS
16 Maggio 2022

SIFI and RADICEPURA announce the closure of the International Call For Ideas to design a Green Area and an Educational Park
22 Marzo 2022

SIFI Announces the Grant of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis
14 Marzo 2022

SIFI PROVIDES REGULATORY UPDATES FOR AKANTIOR® (POLIHEXANIDE 0.8 MG/ML) IN EUROPE AND THE UNITED STATES
15 Febbraio 2022